Please enter the email address you used to register, then we will send you a link to choose a new password
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of...
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market...
The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closi...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmace...